||beta2 agonist, bronchodilator
- 0.25 to 0.5 mg (up to 1 mg) q 4 - 6 h
- IV bolus:
- 250 mcg (~ 4 mcg/kg) over 2-5 mins
- 5 mcg/min, increase by 5 mcg/min to a maximum of 20 mcg/min
5 mg/500 mL D5W, NS
- dextrose containing solutions may be inappropriate for patients with diabetes because of salbutamol induced exaggerated hyperglycemia
||more common with parenteral therapy than inhalational therapy
- with inhalation:
- nervousness, tremor
- with intravenous therapy:
- hypertension or hypotension
- in patients with cardiovascular disorders, hyperthyroidism and diabetes
- salbutamol + sympathomimetics = exacerbation of cardiovascular effects
- salbutamol + beta blockers = mutual antagonism of therapeutic effect
- salbutamol + general anaesthetics = decreased BP, increased HR
- breath sounds
- respiratory rate
- ventilatory pressures
- blood gases
- Adverse effects:
- heart rate, ECG
- serum glucose
- serum potassium
- May be administered by IV infusion by an RN.
- Continuous infusion must be administered via an infusion pump.
- With IV use, patient requires placement of an arterial line .
- With IV use, patient must have continuous ECG monitoring.
- The physician must be present at the initiation of intravenous therapy; subsequent monitoring may be done by an RN.